Stephen P Finn
Overview
Explore the profile of Stephen P Finn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
2470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haberecker M, Ruschoff J, Andriakopoulou C, Gray S, Nackaerts K, de Perrot M, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400675.
PMID: 39938010
Purpose: CD276 (B7-H3) is an immunoregulatory protein that plays an important role in the inhibition of T-cell function. CD276 is overexpressed on a variety of human solid cancer cells with...
2.
Murchan P, Broin P, Baird A, Sheils O, Finn S
J Pathol Inform
. 2024 Oct;
15:100396.
PMID: 39398947
Background: Developing artificial intelligence (AI) models for digital pathology requires large datasets from multiple sources. However, without careful implementation, AI models risk learning confounding site-specific features in datasets instead of...
3.
Huang L, Winter S, Olsson L, Hamilton A, Halliday S, Kirk E, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Sep;
33(12):1623-1632.
PMID: 39269980
Background: Vigorous physical activity has been associated with lower risk of fatal prostate cancer. However, mechanisms contributing to this relationship are not understood. Methods: We studied 117 men with prostate...
4.
Soo R, Dafni U, Han J, Cho B, Nadal E, Yeo C, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5180-5191.
PMID: 39250635
Purpose: The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms...
5.
Vaselkiv J, Shui I, Grob S, Ericsson C, Giovannucci I, Peng C, et al.
Carcinogenesis
. 2024 Aug;
45(10):735-744.
PMID: 39120256
High circulating vitamin D levels and supplementation may lower prostate cancer mortality. To probe for direct effects of vitamin D signaling in the primary tumor, we assessed how activation of...
6.
Saini V, Oner E, Ward M, Hurley S, Henderson B, Lewis F, et al.
Mol Oncol
. 2024 Aug;
PMID: 39105395
Circulating tumor cells (CTCs) have potential as diagnostic, prognostic, and predictive biomarkers in solid tumors. Despite Food and Drug Administration (FDA) approval of CTC devices in various cancers, the rarity...
7.
Speel E, Dafni U, Thunnissen E, Ruschoff J, OBrien C, Kowalski J, et al.
Lung Cancer
. 2024 Jul;
194:107860.
PMID: 39002492
Background: ROS1 fusion is a relatively low prevalence (0.6-2.0%) but targetable driver in lung adenocarcinoma (LUAD). Robust and low-cost tests, such as immunohistochemistry (IHC), are desirable to screen for patients...
8.
Murchan P, Baird A, Broin P, Sheils O, Finn S
Diagnostics (Basel)
. 2024 Mar;
14(5).
PMID: 38472935
Background: Recent advances in computational pathology have shown potential in predicting biomarkers from haematoxylin and eosin (H&E) whole-slide images (WSI). However, predicting the outcome directly from WSIs remains a substantial...
9.
Keogh R, Barr M, Keogh A, McMahon D, OBrien C, Finn S, et al.
JTO Clin Res Rep
. 2024 Feb;
5(2):100627.
PMID: 38333230
Introduction: The identification of genomic "targets" through next-generation sequencing (NGS) of patient's NSCLC tumors has resulted in a rapid expansion of targeted treatment options for selected patients. This retrospective study...
10.
Hannon G, Bogdanska A, Keogh A, Finn S, Gobbo O, Prina-Mello A
Nanotoxicology
. 2023 Nov;
17(8-9):562-580.
PMID: 37982374
Iron oxide nanoparticles (IONP) are showing promise in many biomedical applications. One of these- magnetic hyperthermia- utilizes externally applied alternating magnetic fields and tumor-residing magnetic nanoparticles to generate localized therapeutic...